|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Qi HW, Xin LY, Xu X, Ji XX and Fan LH:
Epithelial-to-mesenchymal transition markers to predict response of
Berberine in suppressing lung cancer invasion and metastasis. J
Transl Med. 12:222014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leber MF and Efferth T: Molecular
principles of cancer invasion and metastasis (Review). Int J Oncol.
34:881–895. 2009.PubMed/NCBI
|
|
4
|
Hamidi H and Ivaska J: Every step of the
way: Integrins in cancer progression and metastasis. Nat Rev
Cancer. 18:533–548. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maziveyi M and Alahari SK: Cell matrix
adhesions in cancer: The proteins that form the glue. Oncotarget.
8:48471–48487. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu H, Gao M, Ma Y, Wang L, Shen Y and Liu
X: Inhibition of cell migration by focal adhesion kinase:
Time-dependent difference in integrin-induced signaling between
endothelial and hepatoblastoma cells. Int J Mol Med. 41:2573–2588.
2018.PubMed/NCBI
|
|
7
|
Mitra SK, Hanson DA and Schlaepfer DD:
Focal adhesion kinase: In command and control of cell motility. Nat
Rev Mol Cell Biol. 6:56–68. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khan KH, Yap TA, Yan L and Cunningham D:
Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J
Cancer. 32:253–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu L, Li F, Cardelli JA, Martin KA,
Blenis J and Huang S: Rapamycin inhibits cell motility by
suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene.
25:7029–7040. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fingar DC, Richardson CJ, Tee AR, Cheatham
L, Tsou C and Blenis J: mTOR controls cell cycle progression
through its cell growth effectors S6K1 and 4E-BP1/eukaryotic
translation initiation factor 4E. Mol Cell Biol. 24:200–216. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Olsson AK, Dimberg A, Kreuger J and
Claesson-Welsh L: VEGF receptor signalling - in control of vascular
function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dimova I, Popivanov G and Djonov V:
Angiogenesis in cancer-general pathways and their therapeutic
implications. J buon. 19:15–21. 2014.PubMed/NCBI
|
|
13
|
Rydén L, Linderholm B, Nielsen NH, Emdin
S, Jönsson PE and Landberg G: Tumor specific VEGF-A and VEGFR2/KDR
protein are co-expressed in breast cancer. Breast Cancer Res Treat.
82:147–154. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tanno S, Ohsaki Y, Nakanishi K, Toyoshima
E and Kikuchi K: Human small cell lung cancer cells express
functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer.
46:11–19. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hamerlik P, Lathia JD, Rasmussen R, Wu Q,
Bartkova J, Lee M, Moudry P, Bartek J Jr, Fischer W, Lukas J, et
al: Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma
stem-like cell viability and tumor growth. J Exp Med. 209:507–520.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu X and Zhou W: The emerging regulation
of VEGFR-2 in triple-negative breast cancer. Front Endocrinol
(Lausanne). 6:1592015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Le Boeuf F, Houle F and Huot J: Regulation
of vascular endothelial growth factor receptor 2-mediated
phosphorylation of focal adhesion kinase by heat shock protein 90
and Src kinase activities. J Biol Chem. 279:39175–39185. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Koch S, Tugues S, Li X, Gualandi L and
Claesson-Welsh L: Signal transduction by vascular endothelial
growth factor receptors. Biochem J. 437:169–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Raistrick H and Smith G: Studies in the
biochemistry of micro-organisms: The metabolic products of
Aspergillus terreus Thom. a new mould metabolic
product-terrein. Biochem J. 29:606–611. 1935. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee JC, Yu MK, Lee R, Lee YH, Jeon JG, Lee
MH, Jhee EC, Yoo ID and Yi HK: Terrein reduces pulpal inflammation
in human dental pulp cells. J Endod. 34:433–437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park SH, Kim DS, Kim WG, Ryoo IJ, Lee DH,
Huh CH, Youn SW, Yoo ID and Park KC: Terrein: A new melanogenesis
inhibitor and its mechanism. Cell Mol Life Sci. 61:2878–2885. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Porameesanaporn Y,
Uthaisang-Tanechpongtamb W, Jarintanan F, Jongrungruangchok S and
Wongsatayanon B: Terrein induces apoptosis in HeLa human cervical
carcinoma cells through p53 and ERK regulation. Oncol Rep.
29:1600–1608. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang F, Mijiti M, Ding W, Song J, Yin Y,
Sun W and Li Z-Y: (+)-Terrein inhibits human hepatoma Bel-7402
proliferation through cell cycle arrest. Oncol Rep. 33:1191–1200.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen YF, Wang SY, Shen H, Yao XF, Zhang FL
and Lai D: The marine-derived fungal metabolite, terrein, inhibits
cell proliferation and induces cell cycle arrest in human ovarian
cancer cells. Int J Mol Med. 34:1591–1598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liao WY, Shen CN, Lin LH, Yang YL, Han HY,
Chen JW, Kuo SC, Wu SH and Liaw CC: Asperjinone, a nor-neolignan,
and terrein, a suppressor of ABCG2-expressing breast cancer cells,
from thermophilic Aspergillus terreus. J Nat Prod.
75:630–635. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shibata A, Ibaragi S, Mandai H, Tsumura T,
Kishimoto K, Okui T, Hassan NM, Shimo T, Omori K, Hu GF, et al:
Synthetic terrein inhibits progression of head and neck cancer by
suppressing angiogenin production. Anticancer Res. 36:2161–2168.
2016.PubMed/NCBI
|
|
27
|
Arakawa M, Someno T, Kawada M and Ikeda D:
A new terrein glucoside, a novel inhibitor of angiogenin secretion
in tumor angiogenesis. J Antibiot (Tokyo). 61:442–448. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kasorn A, Loison F, Kangsamaksin T,
Jongrungruangchok S and Ponglikitmongkol M: Terrein inhibits
migration of human breast cancer cells via inhibition of the Rho
and Rac signaling pathways. Oncol Rep. 39:1378–1386.
2018.PubMed/NCBI
|
|
29
|
Jahng JWS, Alsaadi RM, Palanivel R, Song
E, Hipolito VEB, Sung HK, Botelho RJ, Russell RC and Sweeney G:
Iron overload inhibits late stage autophagic flux leading to
insulin resistance. EMBO Rep. 20:e479112019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sung HK, Song E, Jahng JWS, Pantopoulos K
and Sweeney G: Iron induces insulin resistance in cardiomyocytes
via regulation of oxidative stress. Sci Rep. 9:46682019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee H and Kang KT: Advanced tube formation
assay using human endothelial colony forming cells for in vitro
evaluation of angiogenesis. Korean J Physiol Pharmacol. 22:705–712.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Carpentier G, Berndt S, Ferratge S,
Rasband W, Cuendet M, Uzan G and Albanese P: Angiogenesis analyzer
for ImageJ - A comparative morphometric analysis of ‘endothelial
tube formation assay’ and ‘fibrin bead assay’. Sci Rep.
10:115682020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kumar P, Nagarajan A and Uchil PD:
Analysis of cell viability by the lactate dehydrogenase assay. Cold
Spring Harb Protoc. 2018.2018. View Article : Google Scholar
|
|
35
|
Bendas G and Borsig L: Cancer cell
adhesion and metastasis: Selectins, integrins, and the inhibitory
potential of heparins. Int J Cell Biol. 2012:6767312012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ata R and Antonescu CN: Integrins and cell
metabolism: An intimate relationship impacting cancer. Int J Mol
Sci. 18:1892017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
McCawley LJ and Matrisian LM: Matrix
metalloproteinases: Multifunctional contributors to tumor
progression. Mol Med Today. 6:149–156. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Stetler-Stevenson WG: The role of matrix
metalloproteinases in tumor invasion, metastasis, and angiogenesis.
Surg Oncol Clin N Am. 10:383–392. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li H, Zhang K, Liu LH, Ouyang Y, Bu J, Guo
HB and Xiao T: A systematic review of matrix metalloproteinase 9 as
a biomarker of survival in patients with osteosarcoma. Tumour Biol.
35:5487–5491. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Uchibori M, Nishida Y, Nagasaka T, Yamada
Y, Nakanishi K and Ishiguro N: Increased expression of
membrane-type matrix metalloproteinase-1 is correlated with poor
prognosis in patients with osteosarcoma. Int J Oncol. 28:33–42.
2006.PubMed/NCBI
|
|
41
|
Shen W, Xi H, Wei B and Chen L: The
prognostic role of matrix metalloproteinase 2 in gastric cancer: A
systematic review with meta-analysis. J Cancer Res Clin Oncol.
140:1003–1009. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guo CB, Wang S, Deng C, Zhang DL, Wang FL
and Jin XQ: Relationship between matrix metalloproteinase 2 and
lung cancer progression. Mol Diagn Ther. 11:183–192. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Houghton AM: Matrix metalloproteinases in
destructive lung disease. Matrix Biol. 44-46:167–174. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
El-Badrawy MK, Yousef AM, Shaalan D and
Elsamanoudy AZ: Matrix metalloproteinase-9 expression in lung
cancer patients and its relation to serum mmp-9 activity,
pathologic type, and prognosis. J Bronchology Interv Pulmonol.
21:327–334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zheng S, Chang Y, Hodges KB, Sun Y, Ma X,
Xue Y, Williamson SR, Lopez-Beltran A, Montironi R and Cheng L:
Expression of KISS1 and MMP-9 in non-small cell lung cancer and
their relations to metastasis and survival. Anticancer Res.
30:713–718. 2010.PubMed/NCBI
|
|
46
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Niu G and Chen X: Vascular endothelial
growth factor as an anti-angiogenic target for cancer therapy. Curr
Drug Targets. 11:1000–1017. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mirza AA, Kahle MP, Ameka M, Campbell EM
and Cuevas BD: MEKK2 regulates focal adhesion stability and
motility in invasive breast cancer cells. Biochim Biophys Acta Mol
Cell Res. 1843:945–954. 2014. View Article : Google Scholar
|
|
49
|
Machesky LM: Lamellipodia and filopodia in
metastasis and invasion. FEBS Lett. 582:2102–2111. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Aoudjit F and Vuori K: Integrin signaling
in cancer cell survival and chemoresistance. Chemother Res Pract.
2012:2831812012.PubMed/NCBI
|
|
51
|
Frame MC, Patel H, Serrels B, Lietha D and
Eck MJ: The FERM domain: Organizing the structure and function of
FAK. Nat Rev Mol Cell Biol. 11:802–814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cance WG, Harris JE, Iacocca MV, Roche E,
Yang X, Chang J, Simkins S and Xu L: Immunohistochemical analyses
of focal adhesion kinase expression in benign and malignant human
breast and colon tissues: Correlation with preinvasive and invasive
phenotypes. Clin Cancer Res. 6:2417–2423. 2000.PubMed/NCBI
|
|
53
|
Tai YL, Chen LC and Shen TL: Emerging
roles of focal adhesion kinase in cancer. Biomed Res Int.
2015:6906902015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bouchard V, Demers M-J, Thibodeau S,
Laquerre V, Fujita N, Tsuruo T, Beaulieu J-F, Gauthier R, Vézina A,
Villeneuve L and Vachon PH: Fak/Src signaling in human intestinal
epithelial cell survival and anoikis: Differentiation
state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk
pathways. J Cell Physiol. 212:717–728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Burridge K and Guilluy C: Focal adhesions,
stress fibers and mechanical tension. Exp Cell Res. 343:14–20.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jiang N, Dai Q, Su X, Fu J, Feng X and
Peng J: Role of PI3K/AKT pathway in cancer: The framework of
malignant behavior. Mol Biol Rep. 47:4587–4629. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Brader S and Eccles SA: Phosphoinositide
3-kinase signalling pathways in tumor progression, invasion and
angiogenesis. Tumori. 90:2–8. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Dowling RJO, Topisirovic I, Fonseca BD and
Sonenberg N: Dissecting the role of mTOR: Lessons from mTOR
inhibitors. Biochim Biophys Acta. 1804:433–439. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhou H and Huang S: Role of mTOR signaling
in tumor cell motility, invasion and metastasis. Curr Protein Pept
Sci. 12:30–42. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shih YW, Chen PS, Wu CH, Jeng YF and Wang
CJ: Alpha-chaconine-reduced metastasis involves a PI3K/Akt
signaling pathway with downregulation of NF-kappaB in human lung
adenocarcinoma A549 cells. J Agric Food Chem. 55:11035–11043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wu YJ, Lin SH, Din ZH, Su JH and Liu CI:
Sinulariolide inhibits gastric cancer cell migration and invasion
through downregulation of the EMT process and suppression of
FAK/PI3K/AKT/mTOR and MAPKs signaling pathways. Mar Drugs.
17:6682019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Karar J and Maity A: PI3K/AKT/mTOR pathway
in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI
|
